These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25263790)

  • 1. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.
    Dranka BP; Gifford A; McAllister D; Zielonka J; Joseph J; O'Hara CL; Stucky CL; Kanthasamy AG; Kalyanaraman B
    Neurosci Lett; 2014 Nov; 583():159-64. PubMed ID: 25263790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.
    Dranka BP; Gifford A; Ghosh A; Zielonka J; Joseph J; Kanthasamy AG; Kalyanaraman B
    Neurosci Lett; 2013 Aug; 549():57-62. PubMed ID: 23721786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
    Chen ML; Wu RM
    J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.
    Langley M; Ghosh A; Charli A; Sarkar S; Ay M; Luo J; Zielonka J; Brenza T; Bennett B; Jin H; Ghaisas S; Schlichtmann B; Kim D; Anantharam V; Kanthasamy A; Narasimhan B; Kalyanaraman B; Kanthasamy AG
    Antioxid Redox Signal; 2017 Nov; 27(14):1048-1066. PubMed ID: 28375739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-motor and motor features in LRRK2 transgenic mice.
    Bichler Z; Lim HC; Zeng L; Tan EK
    PLoS One; 2013; 8(7):e70249. PubMed ID: 23936174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
    Gillardon F; Schmid R; Draheim H
    Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
    Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
    Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
    Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.
    Hatano T; Funayama M; Kubo SI; Mata IF; Oji Y; Mori A; Zabetian CP; Waldherr SM; Yoshino H; Oyama G; Shimo Y; Fujimoto KI; Oshima H; Kunii Y; Yabe H; Mizuno Y; Hattori N
    Neurobiol Aging; 2014 Nov; 35(11):2656.e17-2656.e23. PubMed ID: 24973808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.
    Estanga A; Rodriguez-Oroz MC; Ruiz-Martinez J; Barandiaran M; Gorostidi A; Bergareche A; Mondragon E; Lopez de Munain A; Marti-Masso JF
    Parkinsonism Relat Disord; 2014 Oct; 20(10):1097-100. PubMed ID: 25127457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
    Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
    J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
    Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
    Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
    Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
    Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
    Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS
    PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
    Ruiz-Martínez J; de la Riva P; Rodríguez-Oroz MC; Mondragón Rezola E; Bergareche A; Gorostidi A; Gago B; Estanga A; Larrañaga N; Sarasqueta C; López de Munain A; Martí Massó JF
    Mov Disord; 2014 May; 29(6):750-5. PubMed ID: 24357540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 R1441G in Spanish patients with Parkinson's disease.
    Mata IF; Taylor JP; Kachergus J; Hulihan M; Huerta C; Lahoz C; Blazquez M; Guisasola LM; Salvador C; Ribacoba R; Martinez C; Farrer M; Alvarez V
    Neurosci Lett; 2005 Jul; 382(3):309-11. PubMed ID: 15925109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
    Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
    PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olfaction in LRRK2 Linked Parkinson's Disease: Is It Different from Idiopathic Parkinson's Disease?
    Vilas D; Tolosa E; Quintana M; Pont-Sunyer C; Santos M; Casellas A; Valldeoriola F; Compta Y; Martí MJ; Mullol J
    J Parkinsons Dis; 2020; 10(3):951-958. PubMed ID: 32310189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.
    Maekawa T; Mori S; Sasaki Y; Miyajima T; Azuma S; Ohta E; Obata F
    Mol Neurodegener; 2012 Apr; 7():15. PubMed ID: 22534020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.